Q&A Genmab 2020-11-27

	27/11 16:12 af Jan Van de Winkel	Currently the Corona Virus is impacting our programs in some clinical sites, but this impact may be smaller than the impact the pandemic has on large phase 3 studies by other parties. So in that sense, we are progressing to further limit the gap between us and competitors.
	27/11 16:11 af Jan Van de Winkel	We are very actively broadening the clinical programs for epcoritamab and are making excellent progress on multiple fronts..
	27/11 16:10 af GeorgeBest	You have previously mentioned that you aim to narrow the gap timewise for getting epcoritamab to marked compared to the Roche cd3/cd20 drug candidates. Are there any indications that you succeded in narrowing the gap?
	27/11 16:09 af Jan Van de Winkel	Genmab ID is evaluating some of our next gen antibody platforms for a number of infectious pathogens. This in order to assess whether our unique next gen platforms provide a benefit for treatment of diseases caused by these pathogens.
	27/11 16:07 af E L	Genmab recently had an application for an Infectious Diseases Scientist. Could you say something about the ”Genmab Infectious Disease initiative”? Is it only cancer related or is it broader? Is it related to your partnership with ImmunoPrecise as they announced last week?
	27/11 16:07 af Jan Van de Winkel	In our preclinical and research team we also work on other classes of antibodies for novel therapeutic concepts. None of these are yet ready for clinical evaluation.
	27/11 16:06 af Sukkeralf	Have Genmab any active research into other classes of antibodies besides IgG?
	27/11 16:06 af Jan Van de Winkel	AXL is more challenging than anticipated on the basis of the preclinical work, but may well be pursued as a target for cancer therapy with combinations of therapeutics.
	27/11 16:05 af Sukkeralf	After discontinuing enapotamab vedotin whats your view on AXL as a target?
	27/11 16:05 af Jan Van de Winkel	Now, let us turn to your inspirational questions.
	27/11 16:05 af Jan Van de Winkel	So, an extremely strong 2020 so far, despite the COVID-19 pandemic..
	27/11 16:04 af Jan Van de Winkel	Operating income was 5.4 billion Kroner compared to 462 million in the first nine months of 2019, driven by higher revenue, bringing us to our net income of 4.2 billion Kroner..
	27/11 16:04 af Jan Van de Winkel	Total expenses in the first nine months of 2020 were 2.6 billion Kroner, with 84% being R&D and 16% G&A..
	27/11 16:04 af Jan Van de Winkel	Darzalex showed continued strong performance in the third quarter, with the first single quarter sales over $1 billion dollars for Q3..
	27/11 16:04 af Jan Van de Winkel	The increase was primarily driven by the upfront payment from AbbVie and higher DARZALEX royalties..
	27/11 16:04 af Jan Van de Winkel	Financial highlights:.. In the first nine months of the year, Revenue came in at 8.1 billion Danish Kroner an increase of nearly 5.6 billion Kroner compared to the first nine months of 2019..
	27/11 16:03 af Jan Van de Winkel	Finally, earlier this week, we announced that we are discontinuing the development of enapotamab vedotin since the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept..
	27/11 16:03 af Jan Van de Winkel	Since the end of the third quarter, we have kept busy with a number of exciting things. In October we submitted the IND for HexaBody-CD38, the second IND Genmab submitted this year. Earlier this month, we presented the first clinical data for DuoBody-PD-L1x4-1BB, a major milestone in our collaboration with BioNTech, at the SITC annual meeting..
	27/11 16:02 af Jan Van de Winkel	In September, we presented key data for tisotumab vedotin, which we are developing with Seagen, from the Phase 2 innovaTV 204 trial during a late-breaking oral presentation at ESMO. Based on these results we, together with Seagen, look forward to submitting a BLA to the FDA under the accelerated approval pathway..
	27/11 16:01 af Jan Van de Winkel	In August we saw the start of the first-in-human trial of DuoBody-CD3x5T4. Recall that we are developing both epco and DuoBody CD3x5T4 as part of our broad Oncology collaboration with AbbVie..
	27/11 16:01 af Jan Van de Winkel	In July we dosed the first patient in an expansion cohort for epcoritamab and we look forward to presenting further epcoritamab data very shortly at the upcoming ASH conference..
	27/11 16:00 af Jan Van de Winkel	On a single day in August, the U.S. FDA granted approvals to Novartis for Kesimpta in relapsing MS and to Janssen for the eighth multiple myeloma indication for DARZALEX. The Kesimpta approval was highly anticipated and we were very pleased that RMS patients in the US had this convenient treatment option approved nearly a month earlier than expected..
	27/11 16:00 af Jan Van de Winkel	We have seen significant advances in our and our partners’ pipelines throughout 2020 and the third quarter was no exception..
	27/11 16:00 af Helge Larsen/PI-redaktør	Can you give us the financial highlights and the key achievements in Q3.

	27/11 15:59 af Helge Larsen/PI-redaktør	Good afternoon Jan van de Winkel. Welcome to Q&A here on ProInvestor.com. We are very happy to have you back here and ready to answer questions from our investors.
	27/11 15:58 af Jan Van de Winkel	Absolutely, and eager to hear your questions.
	27/11 15:58 af Helge Larsen/PI-redaktør	Hi Jan van de Winkel. Are you online?
	23/11 10:41 af Helge Larsen/PI-redaktør	Denne session starter den 27. november kl. 16.